Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02920554 | The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer | recruiting | N/A | 88 | Saint Vincent's Hospital, KoreaOTHER | 1 | May 22, 2024 |
| clinicaltrials |
| NCT06204835 | ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery | recruiting | Phase 1 | 90 | Institute of Automation, Chinese Academy of SciencesOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | recruiting | Phase 2 | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT06418165 | Vienna Hypothermic Oxygenated Machine Perfusion Study(VIHOMPS) | recruiting | — | 500 | Medical University of ViennaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05866783 | Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma(GLITCA) | recruiting | — | 500 | University Hospital, GhentOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06406244 | Efficacy of TEAS on Chronic Pain and Survival in Patients Undergoing Hepatectomy | recruiting | N/A | 524 | West China HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06406634 | Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06397222 | Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC | recruiting | Phase 2 | 23 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06398028 | The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. | recruiting | Phase 4 | 173 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06389422 | Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | recruiting | Phase 3 | 196 | Wen TianfuOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06257030 | The AMARA (As Much As Reasonably Achievable) Study | recruiting | — | 100 | University Hospital of PatrasOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | recruiting | Phase 2 | 111 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 57 | Fujian Medical UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05187312 | Registry for Advanced Endoscopy(ERDB) | recruiting | — | 1,000 | Region StockholmOTHER_GOV | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05714124 | Liver Embolization Approaches for Tumor Management(LEATUM) | recruiting | — | 580 | IRCCS San RaffaeleOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06363006 | Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer | recruiting | Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06241326 | Immunotherapy for Hepatocellular Carcinoma(IFHC) | recruiting | — | 11,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05652920 | Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | recruiting | Phase 1 / Phase 2 | 105 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06340620 | EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope | recruiting | N/A | 140 | Orlando Health, Inc.OTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06326502 | A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 50 | Etnova Therapeutics Corp.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06261125 | Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)(HSBRT2401) | recruiting | Phase 2 | 60 | Mian XIOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05970666 | Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 71 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06265350 | Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | recruiting | N/A | 80 | Sun Yat-sen UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05794048 | METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors(PROMETHEP) | recruiting | N/A | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06236568 | Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation | recruiting | N/A | 40 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06098547 | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)(LIRICA) | recruiting | N/A | 10 | Azienda Sanitaria OspedalieraOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06219096 | Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection | recruiting | N/A | 100 | West China HospitalOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06190665 | DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT04745403 | Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)(SAFE-T-HBV) | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05444478 | Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma | recruiting | N/A | 274 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06044506 | Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma | recruiting | Phase 1 | 3 | Dr Cipto Mangunkusumo General HospitalOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT04616495 | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases(TRASMETIR) | recruiting | — | 30 | Hospital Universitario La FeOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05994859 | SIRT for Potentially Resectable HCC | recruiting | N/A | 35 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05047510 | GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma | recruiting | N/A | 60 | Chinese Academy of SciencesOTHER_GOV | 1 | Aug 30, 2023 | clinicaltrials |
| NCT03637569 | The Relationship Between Triceps Skinfold and Overall Survival of Pancreas, Bile Duct, Gallbladder Cancer | recruiting | — | 1,000 | Samsung Medical CenterOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05502198 | Relevance of Sarcopenia in Advanced Liver Disease(ACCESS-ESLD) | recruiting | — | 150 | Linkoeping UniversityOTHER_GOV | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 20, 2024source: clinicaltrials